Larimar Therapeutics (LRMR) Assets Average (2014 - 2026)

Larimar Therapeutics (LRMR) has reported Assets Average for 13 consecutive years, with $155.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average fell 2.82% year-over-year to $155.6 million; the trailing twelve-month figure through Jun 2026 stood at $155.6 million (down 2.82% YoY), and the FY2025 full-year result was $173.0 million, up 16.85% from the prior year.
• Assets Average fell to $155.6 million in Q2 2026 per LRMR's latest filing, from $166.6 million in the prior quarter.
• Across five years, Assets Average topped out at $242.7 million in Q2 2024 and bottomed at $67.0 million in Q2 2022.
• Historically, Assets Average has averaged $147.3 million across 5 years, with a median of $155.6 million in 2026.
• The sharpest annual moves came in 2024 and 2025: Assets Average soared 111.52% in 2024, then plunged 34.04% in 2025.
• Over 5 years, Assets Average stood at $129.7 million in 2022, then retreated by 22.95% to $99.9 million in 2023, then jumped by 109.74% to $209.6 million in 2024, then fell by 20.53% to $166.6 million in 2025, then decreased by 6.62% to $155.6 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $155.6 million, $166.6 million, and $168.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.